Artelo Biosciences, INC. (ARTL) — SEC Filings

Overview

Artelo Biosciences, INC. (ARTL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 424B3 filed on Apr 16, 2026: Artelo Biosciences, Inc. filed a 424B3 prospectus on April 16, 2026, detailing its offering. The company, located at 505 Lomas Santa Fe, Suite 160, Solana Beach, CA 92075, is involved in the Pharmaceutical Preparations industry. This filing is a standard prospectus supplement.

Sentiment Summary

Across 41 filings, the sentiment breakdown is: 5 bearish, 34 neutral, 2 mixed. The dominant filing sentiment for Artelo Biosciences, INC. is neutral.

Filing Type Overview

Artelo Biosciences, INC. (ARTL) has filed 1 424B3, 2 EFFECT, 24 8-K, 1 D, 1 RW, 2 S-1, 2 DEF 14A, 6 10-Q, 2 10-K with the SEC between Mar 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (41)

• Artelo Biosciences Files 424B3 Prospectus — 424B3 · Apr 16, 2026 Risk: medium
  Artelo Biosciences, Inc. filed a 424B3 prospectus on April 16, 2026, detailing its offering. The company, located at 505 Lomas Santa Fe, Suite 160, Solana Beach
• EFFECT Filing — EFFECT · Apr 16, 2026
• 8-K Filing — 8-K · Apr 7, 2026
• Artelo Biosciences Files Form D for Exempt Offering — D · Apr 6, 2026 Risk: medium
  Artelo Biosciences, Inc. filed a Form D on April 6, 2026, to announce an exempt offering of securities. The company is located at 505 Lomas Santa Fe, Suite 160,
• Artelo Biosciences Withdraws Registration Filing — RW · Mar 27, 2026 Risk: medium
  Artelo Biosciences, Inc. filed a Form RW, a Registration Withdrawal Request, on March 27, 2026. This filing indicates the company is withdrawing a previously fi
• ARTELO BIOSCIENCES Registration Effective; Paves Way for Offering — EFFECT · Mar 26, 2026
  The SEC has declared the registration statement for ARTELO BIOSCIENCES, INC. (CIK: 0001621221) effective as of March 25, 2026. This 'EFFECT' filing, with File N
• Artelo Registers 4.27M Shares for Resale; Eyes $50M from Equity Deal — S-1 · Mar 24, 2026 Risk: high
  Artelo Biosciences, Inc. (ARTL) is a clinical-stage biopharmaceutical company focused on lipid-signaling modulation pathways. The company is not selling any sec
• Artelo Biosciences to Elect Directors, Hold Say-on-Pay Vote at Virtual 2025 AGM — DEF 14A · Dec 11, 2025 Risk: medium
  ARTELO BIOSCIENCES, INC. (ARTL) is holding its 2025 Annual Meeting of Stockholders virtually on December 31, 2025, at 8:00 a.m. Pacific Time. Key proposals incl
• 8-K Filing — 8-K · Nov 25, 2025
• Artelo Files S-1 for Resale of 899,972 Shares; Cancer Drug Shows Promise — S-1 · Nov 17, 2025 Risk: high
  Artelo Biosciences, Inc. (ARTL) is a clinical-stage biopharmaceutical company focused on lipid-signaling modulation pathways. The company is offering to resell
• Artelo Biosciences Files 8-K with Corporate Updates — 8-K · Nov 14, 2025 Risk: low
  Artelo Biosciences, Inc. filed an 8-K on November 14, 2025, reporting on events that occurred on November 10, 2025. The filing indicates amendments to its Artic
• ARTL's Losses Widen Amid Soaring R&D, G&A Costs — 10-Q · Nov 12, 2025 Risk: high
  ARTELO BIOSCIENCES, INC. (ARTL) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $8,713,000, up from $6,048,00
• Artelo Biosciences Files 8-K: Material Agreement & Financial Updates — 8-K · Oct 31, 2025 Risk: medium
  Artelo Biosciences, Inc. entered into a Material Definitive Agreement on October 28, 2025. This agreement also created a Direct Financial Obligation for the reg
• Artelo Biosciences Announces Board and Compensation Changes — 8-K · Oct 27, 2025 Risk: medium
  Artelo Biosciences, Inc. announced on October 26, 2025, changes in its board of directors and executive compensation arrangements. The filing details the depart
• Artelo Biosciences Enters Material Definitive Agreement — 8-K · Oct 17, 2025 Risk: medium
  Artelo Biosciences, Inc. entered into a material definitive agreement on October 15, 2025. The filing also includes financial statements and exhibits related to
• Artelo Biosciences Files 8-K — 8-K · Oct 1, 2025 Risk: medium
  Artelo Biosciences, Inc. filed an 8-K on October 1, 2025, reporting on events that occurred on September 29, 2025. The filing indicates the entry into a materia
• Artelo Biosciences Files 8-K — 8-K · Sep 15, 2025 Risk: low
  Artelo Biosciences, Inc. filed an 8-K on September 15, 2025, reporting an event that occurred on September 11, 2025. The filing pertains to 'Other Events' and i
• Artelo Biosciences Files 8-K with Corporate Updates — 8-K · Sep 10, 2025 Risk: low
  Artelo Biosciences, Inc. filed an 8-K on September 9, 2025, reporting amendments to its Articles of Incorporation or Bylaws and submitting financial statements
• Artelo Biosciences Enters Material Definitive Agreement — 8-K · Sep 5, 2025 Risk: medium
  On September 3, 2025, Artelo Biosciences, Inc. entered into a material definitive agreement. The company, formerly known as Reactive Medical Inc. and Knight Kno
• Artelo Biosciences Files 8-K — 8-K · Sep 3, 2025 Risk: low
  Artelo Biosciences, Inc. filed an 8-K on September 3, 2025, reporting other events. The company, incorporated in Nevada, is based in Solana Beach, CA, and opera
• Artelo Biosciences Files 8-K on Security Holder Vote — 8-K · Aug 29, 2025 Risk: medium
  Artelo Biosciences, Inc. filed an 8-K on August 29, 2025, reporting on a matter submitted to a vote of its security holders on August 28, 2025. The filing does
• Artelo Biosciences Terminates Material Agreement — 8-K · Aug 20, 2025 Risk: medium
  Artelo Biosciences, Inc. filed an 8-K on August 20, 2025, reporting the termination of a material definitive agreement. The filing also includes financial state
• ARTL's Losses Widen Amid Increased R&D, Aggressive Financing Moves — 10-Q · Aug 13, 2025 Risk: high
  ARTELO BIOSCIENCES, INC. (ARTL) reported a net loss of $3,221 thousand for the three months ended June 30, 2025, an increase from $2,433 thousand in the prior y
• Artelo Biosciences Files 8-K on Material Agreement & Equity Sales — 8-K · Aug 7, 2025 Risk: medium
  Artelo Biosciences, Inc. filed an 8-K on August 7, 2025, reporting an entry into a material definitive agreement and unregistered sales of equity securities. Th
• Artelo Biosciences Files 8-K: Material Agreement, Equity Sales — 8-K · Aug 4, 2025 Risk: medium
  On August 1, 2025, Artelo Biosciences, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities a
• Artelo Biosciences Files 8-K: Material Agreement & Exhibits — 8-K · Jul 18, 2025 Risk: medium
  On July 18, 2025, Artelo Biosciences, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial statem
• Artelo Biosciences 8-K: Convertible Notes Details — 8-K · Jul 11, 2025 Risk: medium
  Artelo Biosciences, Inc. filed an 8-K on July 11, 2025, reporting on its financial condition and other events. The filing details convertible notes with provisi
• Artelo Biosciences Files 8-K: Material Agreement & Equity Sales — 8-K · Jun 26, 2025 Risk: medium
  On June 24, 2025, Artelo Biosciences, Inc. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and
• Artelo Biosciences Files 8-K on Security Holder Rights — 8-K · Jun 13, 2025 Risk: medium
  Artelo Biosciences, Inc. filed an 8-K on June 13, 2025, reporting material modifications to the rights of security holders and other events. The filing indicate
• Artelo Biosciences Faces Delisting Notice — 8-K · May 23, 2025 Risk: high
  Artelo Biosciences, Inc. filed an 8-K on May 23, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, previously k
• Artelo Biosciences Q1 2025: Minimal Revenue, Balanced Assets/Liabilities — 10-Q · May 13, 2025 Risk: high
  Artelo Biosciences, Inc. filed its Q1 2025 10-Q report on May 13, 2025, for the period ending March 31, 2025. The company reported minimal revenue, with $0.001
• Artelo Biosciences Files 8-K: Material Agreement & Equity Sales — 8-K · May 1, 2025 Risk: medium
  On April 27, 2025, Artelo Biosciences, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities a
• Artelo Biosciences Faces Delisting Concerns — 8-K · Apr 29, 2025 Risk: high
  Artelo Biosciences, Inc. filed an 8-K on April 29, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing
• Artelo Biosciences Files 2024 10-K — 10-K · Mar 3, 2025 Risk: medium
  Artelo Biosciences, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, formerly known as Reactive Medical Inc. and Knight Knox Devel
• Artelo Biosciences Files 8-K on Security Holder Votes — 8-K · Dec 20, 2024 Risk: low
  Artelo Biosciences, Inc. filed an 8-K on December 20, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specif
• Artelo Biosciences Reports Minimal Revenue in Q3 2024 — 10-Q · Nov 12, 2024 Risk: high
  Artelo Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported minimal revenue, with $0.001 million in revenue for the n
• Artelo Biosciences Proxy Statement Filed for Dec 19 Meeting — DEF 14A · Nov 8, 2024 Risk: medium
  Artelo Biosciences, Inc. filed its definitive proxy statement on November 8, 2024, for its annual meeting of stockholders scheduled for December 19, 2024. The f
• Artelo Biosciences Reports Q2 2024 Results — 10-Q · Aug 13, 2024 Risk: high
  Artelo Biosciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported minimal revenue, with total revenues for the six months ended
• Artelo Biosciences, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: low
  ARTELO BIOSCIENCES, INC. (ARTL) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Artelo Biosciences, Inc. reported financial results for the quarte
• Artelo Biosciences, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 25, 2024 Risk: medium
  ARTELO BIOSCIENCES, INC. (ARTL) filed a Annual Report (10-K) with the SEC on March 25, 2024. Artelo Biosciences, Inc. filed its annual report for the fiscal yea
• Artelo Biosciences Appoints New CMO, Director Diamond Departs — 8-K · Mar 4, 2024 Risk: medium
  Artelo Biosciences, Inc. announced on February 28, 2024, a change in its board of directors. Specifically, Dr. Robert L. Diamond resigned from his position as C

Related Companies

ARLO

Frequently Asked Questions